Price T Rowe Associates Inc. MD Sells 303,653 Shares of argenx SE (NASDAQ:ARGX)

Price T Rowe Associates Inc. MD lessened its stake in argenx SE (NASDAQ:ARGX - Free Report) by 5.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,516,894 shares of the company's stock after selling 303,653 shares during the quarter. Price T Rowe Associates Inc. MD owned 9.08% of argenx worth $3,392,891,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. GeoWealth Management LLC raised its holdings in argenx by 56.3% in the fourth quarter. GeoWealth Management LLC now owns 50 shares of the company's stock worth $31,000 after buying an additional 18 shares during the last quarter. Whipplewood Advisors LLC bought a new stake in shares of argenx during the fourth quarter valued at approximately $37,000. Global Retirement Partners LLC raised its holdings in argenx by 369.2% in the 4th quarter. Global Retirement Partners LLC now owns 61 shares of the company's stock worth $38,000 after acquiring an additional 48 shares during the last quarter. FIL Ltd bought a new position in argenx in the 4th quarter valued at approximately $38,000. Finally, Jones Financial Companies Lllp boosted its stake in argenx by 1,016.7% during the 4th quarter. Jones Financial Companies Lllp now owns 67 shares of the company's stock valued at $41,000 after purchasing an additional 61 shares during the last quarter. Institutional investors own 60.32% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently weighed in on ARGX shares. Wells Fargo & Company boosted their price target on argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. JMP Securities boosted their target price on argenx from $606.00 to $696.00 and gave the stock a "market outperform" rating in a research report on Tuesday, January 14th. Deutsche Bank Aktiengesellschaft raised shares of argenx from a "sell" rating to a "hold" rating in a report on Wednesday, March 12th. Citigroup boosted their price objective on shares of argenx from $681.00 to $796.00 and gave the company a "buy" rating in a report on Thursday, April 17th. Finally, William Blair restated an "outperform" rating on shares of argenx in a report on Friday, February 28th. Three investment analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $699.28.

argenx Price Performance

ARGX opened at $599.87 on Wednesday. The firm has a market cap of $36.45 billion, a P/E ratio of -681.67 and a beta of 0.60. argenx SE has a 1-year low of $352.77 and a 1-year high of $678.21. The company has a 50 day simple moving average of $600.43 and a two-hundred day simple moving average of $606.78.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, February 27th. The company reported $1.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.98 by $0.60. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $761.22 million during the quarter, compared to analyst estimates of $678.52 million. Equities analysts anticipate that argenx SE will post 3.13 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.